Quote from: Vii on April 02, 2016, 12:49:39 PM
You replied to me in another thread where I was worried about too high estrogen levels. That shouldn't be the problem. You can only guess how much of it binds to receptors, but my issue was foremost increased body hair, which I don't think is something estrogen plays a big role in, as to my knowledge it's mostly an effect of DHT.
E does matter to an extent. So, if E is opposed by CPA (due to progestogenic effect, downregulation of receptors, more estradiol converted to estrone), and was slightly higher on Spiro, it could have made a difference.
J Invest Dermatol. 1997 Sep;109(3):296-300."Androgen receptor content in female frontal hair follicles was approximately 40% lower than in male frontal hair follicle. Cytochrome P-450-aromatase content in women's frontal hair follicles was six times greater than in frontal hair follicles in men. Frontal hair follicles in women had 3 and 3.5 times less 5alpha-reductase type I and II, respectively, than frontal hair follicles in men."
Suggesting *perhaps* estrogen reduces androgen receptors, increases aromatase and reduces conversion of T to DHT by resulting in less 5 alpha reductase activity.
Endocrinology. 1987 Jun;120(6):2597-603."In summary, estradiol treatment caused a reduction in androgen receptors, and estradiol withdrawal lead to a rise in androgen receptors. We believe that these results provide a mechanism whereby estradiol may directly antagonize androgen action."
Exp Dermatol. 2002 Aug;11(4):376-80."For topical treatment of androgenetic alopecia (AGA) in women, solutions containing either estradiol benzoate, estradiol valerate, 17beta- or 17alpha-estradiol are commercially available in Europe and some studies show an increased anagen and decreased telogen rate after treatment as compared with placebo."
"In conclusion, our ex vivo experiments suggest that under the influence of 17alpha-estradiol an increased conversion of testosterone to 17beta-estradiol and androstendione to estrone takes place, which might explain the beneficial effects of estrogen treatment of AGA"
QuoteThe study I quoted and also pretty much any other you can find on the matter cites patients taking CPA 4 years or longer who have had meningioma growth. By the time I have my SRS and with it, an orchiectomy, I'll have been on CPA for half a year so the fastest known case took 8 times that to become an issue.
Right, I understand now (I misunderstood) BUT I still wouldn't take the risk. To each their own. But why continue on it anyways if you are seeing increased androgenic effects on it?